Cargando…

Efficacy and Safety of Pemafibrate Versus Bezafibrate to Treat Patients with Hypertriglyceridemia: A Randomized Crossover Study

Mostrar otras versiones (1)

Detalles Bibliográficos
Autores principales:	Nakamura, Akihiro, Kagaya, Yuta, Saito, Hiroki, Kanazawa, Masanori, Sato, Kenjiro, Miura, Masanobu, Kondo, Masateru, Endo, Hideaki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Japan Atherosclerosis Society 2023
Materias:	Erratum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10244067/ https://www.ncbi.nlm.nih.gov/pubmed/37150612 http://dx.doi.org/10.5551/jat.ER63659

Ejemplares similares

Efficacy and Safety of Pemafibrate Versus Bezafibrate to Treat Patients with Hypertriglyceridemia: A Randomized Crossover Study
por: Nakamura, Akihiro, et al.
Publicado: (2023)

Effects of switching from sacubitril/valsartan to valsartan alone on plasma levels of natriuretic peptides and myocardial remodeling in heart failure with reduced ejection fraction
por: Nakamura, Akihiro, et al.
Publicado: (2023)

Bezafibrate improves postprandial hypertriglyceridemia and associated endothelial dysfunction in patients with metabolic syndrome: a randomized crossover study
por: Ohno, Yuko, et al.
Publicado: (2014)

Impact of decreased insulin resistance by ezetimibe on postprandial lipid profiles and endothelial functions in obese, non-diabetic-metabolic syndrome patients with coronary artery disease
por: Nakamura, Akihiro, et al.
Publicado: (2018)

Decline of popliteal artery flow-mediated dilation with aging and possible involvement of asymmetric dimethylarginine in healthy men
por: Nakamura, Akihiro, et al.
Publicado: (2019)

A case of hyperlipoprotein(a)emia undergoing catheter interventions for coronary artery disease, aortic valve stenosis, and peripheral artery disease
por: Nakamura, Akihiro, et al.
Publicado: (2022)

Functional and Structural Insights into Human PPARα/δ/γ Subtype Selectivity of Bezafibrate, Fenofibric Acid, and Pemafibrate
por: Honda, Akihiro, et al.
Publicado: (2022)

A Significant Effect of Pemafibrate on Hepatic Steatosis and Fibrosis Indexes in Patients With Hypertriglyceridemia
por: Katsuyama, Hisayuki, et al.
Publicado: (2023)

Systematic review and meta-analysis: bezafibrate in patients with primary biliary cirrhosis [Erratum]
Publicado: (2015)

Sudden failure of ventricular pacing and recovery in a patient with cardiac sarcoidosis
por: Terui, Yosuke, et al.
Publicado: (2017)

Half Dose Once-Daily Pemafibrate Effectively Improved Hypertriglyceridemia in Real Practice
por: Iitake, Chie, et al.
Publicado: (2019)

Effect of 48‐week pemafibrate on non‐alcoholic fatty liver disease with hypertriglyceridemia, as evaluated by the FibroScan‐aspartate aminotransferase score
por: Hatanaka, Takeshi, et al.
Publicado: (2021)

Efficacy and Safety of Low-Dose Pemafibrate Therapy for Hypertriglyceridemia in Patients with Type 2 Diabetes
por: Bando, Hidenori, et al.
Publicado: (2021)

Effects of Pemafibrate in Patients with Stroke and Hypertriglyceridemia: Baseline Cerebral Artery Diseases and 3-Month Laboratory Outcomes
por: Hoshino, Takao, et al.
Publicado: (2022)

Impact of Pemafibrate Therapy on Reducing Small Dense Low-Density-Lipoprotein-Cholesterol Levels in Patients with Hypertriglyceridemia
por: Hida, Yuki, et al.
Publicado: (2023)

The effect of bezafibrate and omega-3 fatty acids on lymphocyte cytokine release and systemic inflammation in patients with isolated hypertriglyceridemia
por: Krysiak, Robert, et al.
Publicado: (2011)

Comparison of the measured pre-ejection periods and left ventricular ejection times between echocardiography and impedance cardiography for optimizing cardiac resynchronization therapy
por: Noda, Kazuki, et al.
Publicado: (2017)

Effect of Pemafibrate on Hemorheology in Patients with Hypertriglyceridemia and Aggravated Blood Fluidity Associated with Type 2 Diabetes or Metabolic Syndrome
por: Iwakura, Tomohiro, et al.
Publicado: (2023)

Impact of Pemafibrate in Patients with Hypertriglyceridemia and Metabolic Dysfunction-associated Fatty Liver Disease Pathologically Diagnosed with Non-alcoholic Steatohepatitis: A Retrospective, Single-arm Study
por: Hatanaka, Takeshi, et al.
Publicado: (2021)

Pemafibrate Prevents Rupture of Angiotensin II-Induced Abdominal Aortic Aneurysms
por: Amioka, Naofumi, et al.
Publicado: (2022)

A Novel Selective PPARα Modulator (SPPARMα), K-877 (Pemafibrate), Attenuates Postprandial Hypertriglyceridemia in Mice
por: Sairyo, Masami, et al.
Publicado: (2018)

Marked effects of novel selective peroxisome proliferator-activated receptor α modulator, pemafibrate in severe hypertriglyceridemia: preliminary report
por: Iitake, Chie, et al.
Publicado: (2020)

Erratum:A Novel Selective PPARα Modulator (SPPARMα), K-877 (Pemafibrate), Attenuates Postprandial Hypertriglyceridemia in Mice
por: Sairyo, Masami, et al.
Publicado: (2018)

Transradial peripheral vascular intervention using Fowler’s position and Terumo R2P system for patients with heart failure: two case reports
por: Nakamura, Akihiro, et al.
Publicado: (2022)

Combined effect of obesity and uric acid on nonalcoholic fatty liver disease and hypertriglyceridemia: Erratum
Publicado: (2017)

Favorable Effect of Pemafibrate on Insulin Resistance and β-Cell Function in Subjects with Type 2 Diabetes and Hypertriglyceridemia: A Subanalysis of the PARM-T2D Study
por: Nomoto, Hiroshi, et al.
Publicado: (2023)

Bezafibrate for X-Linked Adrenoleukodystrophy
por: Engelen, Marc, et al.
Publicado: (2012)

Therapy of Canine Hyperlipidemia with Bezafibrate
por: De Marco, V., et al.
Publicado: (2017)

Update on the use of fibrates: focus on bezafibrate
por: Goldenberg, Ilan, et al.
Publicado: (2008)

Metabolic effects of bezafibrate in mitochondrial disease
por: Steele, Hannah, et al.
Publicado: (2020)

Erratum to: A novel APOC2 gene mutation identified in a Chinese patient with severe hypertriglyceridemia and recurrent pancreatitis
por: Jiang, Jingjing, et al.
Publicado: (2016)

Effects of a novel selective peroxisome proliferator‐activated receptor‐α modulator, pemafibrate, on hepatic and peripheral glucose uptake in patients with hypertriglyceridemia and insulin resistance
por: Matsuba, Ikuro, et al.
Publicado: (2018)

Pemafibrate improves liver dysfunction and non-invasive surrogates for liver fibrosis in patients with non-alcoholic fatty liver disease with hypertriglyceridemia: a multicenter study
por: Morishita, Asahiro, et al.
Publicado: (2022)

Osteoblastic differentiation improved by bezafibrate-induced mitochondrial biogenesis in deciduous tooth-derived pulp stem cells from a child with Leigh syndrome
por: Han, Xu, et al.
Publicado: (2018)

Percutaneous transradial artery approach for femoro- popliteal artery intervention in the current era in Japan
por: Nakamura, Akihiro, et al.
Publicado: (2018)

Bezafibrate Ameliorates Arterial Stiffness Assessed by Cardio-Ankle Vascular Index in Hypertriglyceridemic Patients with Type 2 Diabetes Mellitus
por: Yamaguchi, Takashi, et al.
Publicado: (2019)

Pemafibrate decreases triglycerides and small, dense LDL, but increases LDL-C depending on baseline triglycerides and LDL-C in type 2 diabetes patients with hypertriglyceridemia: an observational study
por: Komiya, Ichiro, et al.
Publicado: (2021)

An Ultrathin Endoscope with a 2.4-mm Working Channel Shortens the Esophagogastroduodenoscopy Time by Shortening the Suction Time
por: Shinozaki, Satoshi, et al.
Publicado: (2016)

Erratum: Diurnal variation of urinary sodium-to-potassium ratio in free-living Japanese individuals
por: Iwahori, Toshiyuki, et al.
Publicado: (2017)

Antidiabetic Action of Bezafibrate in a Large Observational Database
por: Flory, James H., et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_u65qalj2gh7dh5v7a6anm0ru7v